Abstract
Nerve growth factor (NGF) has long been known for its effects on neuronal cell survival and differentiation. This prototypical neurotrophic factor stimulates neurons through two distinct classes of membrane receptors: the TrkA tyrosine kinase receptor, and the tumor necrosis factor receptor family member p75NTR, also known as the common neurotrophin receptor. Somewhat surprisingly, there is a growing body of evidence indicating that NGF is also a major stimulator of breast cancer cell growth. Both the survival and proliferation of breast cancer cells are strongly stimulated by NGF, mediated by TrkA and p75NTR respectively, utilising signaling pathways similar to those described for neurons. In addition, although NGF is produced by breast cancer cells, it is not in normal breast epithelial cells, giving rise to an autocrine stimulation of tumor growth. Therefore, NGF receptors and signaling are thus looking increasingly promising as potential drug targets for breast cancer.
Keywords: breast cancer, nerve growth factor, receptors and signaling, therapeutic target
Current Cancer Drug Targets
Title: Nerve Growth Factor Receptors and Signaling in Breast Cancer
Volume: 4 Issue: 6
Author(s): Laurent Dolle, Eric Adriaenssens, Ikram El Yazidi-Belkoura, Xuefen Le Bourhis, Victor Nurcombe and Hubert Hondermarck
Affiliation:
Keywords: breast cancer, nerve growth factor, receptors and signaling, therapeutic target
Abstract: Nerve growth factor (NGF) has long been known for its effects on neuronal cell survival and differentiation. This prototypical neurotrophic factor stimulates neurons through two distinct classes of membrane receptors: the TrkA tyrosine kinase receptor, and the tumor necrosis factor receptor family member p75NTR, also known as the common neurotrophin receptor. Somewhat surprisingly, there is a growing body of evidence indicating that NGF is also a major stimulator of breast cancer cell growth. Both the survival and proliferation of breast cancer cells are strongly stimulated by NGF, mediated by TrkA and p75NTR respectively, utilising signaling pathways similar to those described for neurons. In addition, although NGF is produced by breast cancer cells, it is not in normal breast epithelial cells, giving rise to an autocrine stimulation of tumor growth. Therefore, NGF receptors and signaling are thus looking increasingly promising as potential drug targets for breast cancer.
Export Options
About this article
Cite this article as:
Dolle Laurent, Adriaenssens Eric, Yazidi-Belkoura El Ikram, Bourhis Le Xuefen, Nurcombe Victor and Hondermarck Hubert, Nerve Growth Factor Receptors and Signaling in Breast Cancer, Current Cancer Drug Targets 2004; 4 (6) . https://dx.doi.org/10.2174/1568009043332853
DOI https://dx.doi.org/10.2174/1568009043332853 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacogenomic Approaches to Osteoporosis: 2005 Update
Current Pharmacogenomics Evaluation of Dendrimer Safety and Efficacy through Cell Line Studies
Current Drug Targets Graphical Abstracts
Letters in Drug Design & Discovery Exploiting Significance of Physical Exercise in Prevention of Gastrointestinal Disorders
Current Pharmaceutical Design Mechanisms of Drug-Induced Mitotic Catastrophe in Cancer Cells
Current Pharmaceutical Design A Rationale for the Use of Proton Pump Inhibitors as Antineoplastic Agents
Current Pharmaceutical Design Phytochemicals: Key to Effective Anticancer Drugs
Mini-Reviews in Organic Chemistry Anti-cancer Peptides from Ras-P21 and P53 Proteins
Current Pharmaceutical Design Estrogen Receptors as Therapeutic Targets in Breast Cancer
Current Topics in Medicinal Chemistry Histopathology of Ductal Carcinoma in Situ (DCIS) of the Breast
Current Cancer Therapy Reviews Raloxifene
Current Drug Targets The Role of Organic Transporters in Pharmacokinetics and Nephrotoxicity of Newer Antiviral Therapies for HIV and Hepatitis C
Current Drug Metabolism Calcium-calpain Dependent Pathways Regulate Vesiculation in Malignant Breast Cells
Current Cancer Drug Targets Effects of Endocrine Disruptors on Developmental and Reproductive Functions
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Spermine Metabolism and Anticancer Therapy
Current Cancer Drug Targets Radiotracers for Molecular Imaging of Cyclooxygenase-2 (COX-2) Enzyme
Current Medicinal Chemistry Engineered Silver Nanoparticles, A New Nanoweapon Against Cancer
Anti-Cancer Agents in Medicinal Chemistry The Psychiatric Drug Lithium Increases DNA Damage and Decreases Cell Survival in MCF-7 and MDA-MB-231 Breast Cancer Cell Lines Expos ed to Ionizing Radiation
Current Molecular Pharmacology 3D QSAR Pharmacophore Modeling for c-Met Kinase Inhibitors
Medicinal Chemistry Potentiation of Anti-Cancer Treatment by Modulators of Energy Metabolism
Current Pharmaceutical Biotechnology